Oral Arginine Reduces Amyloid Buildup in Alzheimer’s Models

Arginine supplementation curbs Alzheimer's disease pathology in animal models

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies that target amyloid β (Aβ) have recently been developed, their clinical effectiveness remains limited. These treatments can be costly and cause immune-related side effects, highlighting the need for safer, affordable, and widely accessible approaches that c…

Oral arginine reduces amyloid buildup in Alzheimer’s models

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies that target amyloid β (Aβ) have recently been developed, their clinical effectiveness remains limited.

Simple amino acid supplement greatly reduces Alzheimer’s damage

Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in Alzheimer’s disease models. In flies and mice, oral arginine lowered plaque levels, reduced inflammation, and improved behavior. Its strong safety record and low cost make it a promising repurposing candidate. The findings hint at a surprisingly simple path toward more accessible AD therapies.

Environmental News Network - Oral Arginine Reduces Amyloid Buildup in Alzheimer’s Models

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure.

Oral Arginine Reduces Amyloid Buildup in Alzheimer’s Models

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure.

Supplement Shows Promise in Blocking Amyloid in Alzheimer’s

A new study shows that oral arginine, a naturally occurring amino acid, can significantly suppress amyloid-β aggregation in Alzheimer’s disease models. Researchers found that arginine not only prevented Aβ42 from clumping but also reduced plaques and inflammation in mouse and fruit fly models carrying Alzheimer’s-related mutations.